Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Axonics reports Q2 EPS (54c), consensus (65c) » 16:10
08/06/20
08/06
16:10
08/06/20
16:10
AXNX

Axonics

$43.35 /

-1.16 (-2.61%)

Reports Q2 revenue $15.2M…

Reports Q2 revenue $15.2M vs. $1.5M last year. Cash used in operating activities in the second quarter 2020 was $13.0 million. As of June 30, 2020, cash and cash equivalents were $288 million.

ShowHide Related Items >><<
AXNX Axonics
$43.35 /

-1.16 (-2.61%)

AXNX Axonics
$43.35 /

-1.16 (-2.61%)

08/04/20 Piper Sandler
Proposed CMS rates positive for neuromodulation names, says PiperSandler
08/03/20 Piper Sandler
Piper says Axonics positioned for continued share taking despite Medtronic nod
07/27/20 Piper Sandler
Axonics data 'strong and consistent' with one-year results, says Piper Sandler
04/21/20 Piper Sandler
Axonics price target lowered to $44 from $48 at Piper Sandler
AXNX Axonics
$43.35 /

-1.16 (-2.61%)

  • 08
    May
  • 20
    Nov
AXNX Axonics
$43.35 /

-1.16 (-2.61%)

Over a week ago
Recommendations
Proposed CMS rates positive for neuromodulation names, says PiperSandler » 14:14
08/04/20
08/04
14:14
08/04/20
14:14
AXNX

Axonics

$43.31 /

+0.18 (+0.42%)

, INSP

Inspire Medical

$103.22 /

+1.82 (+1.79%)

, LIVN

LivaNova

$46.08 /

-0.04 (-0.09%)

The Centers for Medicare…

The Centers for Medicare and Medicaid Services earlier today issued its proposed rule for 2021 for the rate of Medicare facility reimbursement in the hospital outpatient department and ambulatory surgery center settings, Piper Sandler analyst Adam Maeder tells investors in a research note. The analyst views the proposed changes as favorable for the neuromodulation names he follows such as Axonics (AXNX), Inspire Medical (INSP) and LivaNova (LIVN). The 2021 proposed rate of facility reimbursement for a permanent sacral neuromodulation implant s $20,790, up 8% year-over-year, in the hospital outpatient department and $18,305, up 6%, for procedures done in ambulatory surgery centers, says the analyst.

ShowHide Related Items >><<
LIVN LivaNova
$46.08 /

-0.04 (-0.09%)

INSP Inspire Medical
$103.22 /

+1.82 (+1.79%)

AXNX Axonics
$43.31 /

+0.18 (+0.42%)

AXNX Axonics
$43.31 /

+0.18 (+0.42%)

08/03/20 Piper Sandler
Piper says Axonics positioned for continued share taking despite Medtronic nod
07/27/20 Piper Sandler
Axonics data 'strong and consistent' with one-year results, says Piper Sandler
04/21/20 Piper Sandler
Axonics price target lowered to $44 from $48 at Piper Sandler
04/14/20 Piper Sandler
Axonics next-gen INS not compatible with InterStim II leads, says Piper Sandler
INSP Inspire Medical
$103.22 /

+1.82 (+1.79%)

07/15/20 Goldman Sachs
Inspire Medical initiated with a Buy at Goldman Sachs
06/29/20 SVB Leerink
Inspire Medical price target raised to $110 from $85 at SVB Leerink
06/18/20 Piper Sandler
Inspire Medical price target raised to $98 from $81 at Piper Sandler
05/26/20 Wells Fargo
Inspire Medical price target raised to $95 from $81 at Wells Fargo
LIVN LivaNova
$46.08 /

-0.04 (-0.09%)

07/29/20 Piper Sandler
LivaNova price target lowered to $60 from $65 at Piper Sandler
06/26/20 Needham
LivaNova price target lowered to $76 from $84 at Needham
05/20/20 Piper Sandler
LivaNova's RECOVER study should ultimately prove positive, says Piper Sandler
04/29/20 Piper Sandler
LivaNova price target lowered to $65 from $80 at Piper Sandler
LIVN LivaNova
$46.08 /

-0.04 (-0.09%)

INSP Inspire Medical
$103.22 /

+1.82 (+1.79%)

AXNX Axonics
$43.31 /

+0.18 (+0.42%)

  • 08
    May
  • 14
    Apr
  • 20
    Nov
LIVN LivaNova
$46.08 /

-0.04 (-0.09%)

INSP Inspire Medical
$103.22 /

+1.82 (+1.79%)

INSP Inspire Medical
$103.22 /

+1.82 (+1.79%)

AXNX Axonics
$43.31 /

+0.18 (+0.42%)

Recommendations
Piper says Axonics positioned for continued share taking despite Medtronic nod » 10:19
08/03/20
08/03
10:19
08/03/20
10:19
AXNX

Axonics

$42.90 /

+0.58 (+1.37%)

, MDT

Medtronic

$96.47 /

-0.06 (-0.06%)

After Medtronic (MDT)…

After Medtronic (MDT) announced that it received FDA approval for its next-gen InterStim Micro device for the treatment of overactive bladder, fecal incontinence and non-obstructive urinary retention, Piper Sandler analyst Adam Maeder said he believes the FDA nod should help the company narrow the competitive gap some from a technology standpoint, but he still sees Axonics (AXNX) having the better product and being well-positioned for continued, "meaningful, durable" share capture. Maeder, who reiterates an Overweight rating and $45 price target on Axonics shares, would recommend investors buy on any weakness following the Medtronic news.

ShowHide Related Items >><<
MDT Medtronic
$96.47 /

-0.06 (-0.06%)

AXNX Axonics
$42.90 /

+0.58 (+1.37%)

AXNX Axonics
$42.90 /

+0.58 (+1.37%)

07/27/20 Piper Sandler
Axonics data 'strong and consistent' with one-year results, says Piper Sandler
04/21/20 Piper Sandler
Axonics price target lowered to $44 from $48 at Piper Sandler
04/14/20 Piper Sandler
Axonics next-gen INS not compatible with InterStim II leads, says Piper Sandler
04/08/20 Wells Fargo
Axonics price target lowered to $35 from $47 at Wells Fargo
MDT Medtronic
$96.47 /

-0.06 (-0.06%)

07/17/20 B. Riley FBR
B. Riley FBR starts ClearPoint at Buy, sees potential takeover
07/16/20 Goldman Sachs
J&J delay to robotic surgery program a positive for Intuitive, says Goldman
07/09/20 Piper Sandler
Tandem, Medtronic deal meant to mitigate litigation risk, says Piper Sandler
MDT Medtronic
$96.47 /

-0.06 (-0.06%)

AXNX Axonics
$42.90 /

+0.58 (+1.37%)

  • 08
    May
  • 20
    Nov
MDT Medtronic
$96.47 /

-0.06 (-0.06%)

MDT Medtronic
$96.47 /

-0.06 (-0.06%)

AXNX Axonics
$42.90 /

+0.58 (+1.37%)

MDT Medtronic
$96.47 /

-0.06 (-0.06%)

Recommendations
Axonics data 'strong and consistent' with one-year results, says Piper Sandler » 09:52
07/27/20
07/27
09:52
07/27/20
09:52
AXNX

Axonics

$40.12 /

+0.995 (+2.54%)

, MDT

Medtronic

$96.01 /

-0.27 (-0.28%)

Piper Sandler analyst…

Piper Sandler analyst Adam Maeder reiterates an Overweight rating on Axonics Modulation Technologies with a $45 price target saying the two-year top-line results from its ARTISAN-SNM U.S. pivotal trial appear "strong and consistent" with the one-year results. At two years, 88% of all implanted patients were therapy responders, which compares to the one-year responder rate of 89%, Maeder tells investors in a research note. It is encouraging to see the durable treatment effect with r-SNM at two years, says the analyst, who views ARTISAN-SNM as the "most compelling" clinical evidence in the sacral neuromodulation category to date. Given that Medtronic (MDT) elected to not run a U.S. pivotal trial to support regulatory approval for InterStim Micro, the ARTISAN-SNM data will likely be a primary selling point and competitive advantage for Axonics in the field, contends Maeder.

ShowHide Related Items >><<
MDT Medtronic
$96.01 /

-0.27 (-0.28%)

AXNX Axonics
$40.12 /

+0.995 (+2.54%)

AXNX Axonics
$40.12 /

+0.995 (+2.54%)

04/21/20 Piper Sandler
Axonics price target lowered to $44 from $48 at Piper Sandler
04/14/20 Piper Sandler
Axonics next-gen INS not compatible with InterStim II leads, says Piper Sandler
04/08/20 Wells Fargo
Axonics price target lowered to $35 from $47 at Wells Fargo
03/05/20 Truist
Axonics price target raised to $48 from $38 at SunTrust
MDT Medtronic
$96.01 /

-0.27 (-0.28%)

07/17/20 B. Riley FBR
B. Riley FBR starts ClearPoint at Buy, sees potential takeover
07/16/20 Goldman Sachs
J&J delay to robotic surgery program a positive for Intuitive, says Goldman
07/09/20 Piper Sandler
Tandem, Medtronic deal meant to mitigate litigation risk, says Piper Sandler
06/30/20 Stifel
Tandem Diabetes target raised to $80 after UnitedHealth coverage news at Stifel
MDT Medtronic
$96.01 /

-0.27 (-0.28%)

AXNX Axonics
$40.12 /

+0.995 (+2.54%)

  • 08
    May
  • 20
    Nov
MDT Medtronic
$96.01 /

-0.27 (-0.28%)

MDT Medtronic
$96.01 /

-0.27 (-0.28%)

AXNX Axonics
$40.12 /

+0.995 (+2.54%)

MDT Medtronic
$96.01 /

-0.27 (-0.28%)

Hot Stocks
Axonics completes clinical results from its ARTISAN-SNM pivotal study » 06:02
07/27/20
07/27
06:02
07/27/20
06:02
AXNX

Axonics

$39.12 /

-0.87 (-2.18%)

Axonics Modulation…

Axonics Modulation Technologies announced completion of 2-year follow-ups and topline clinical results from its ARTISAN-SNM pivotal study that was conducted to evaluate the safety and efficacy of the Axonics r-SNM System. The 2-year study results demonstrate that patients implanted with the Axonics r-SNM System continue to receive clinically meaningful and statistically significant improvements in urinary urgency incontinence symptoms and quality of life. At 2 years, 88% of all implanted patients were therapy responders, consistent with the 89% therapy responder rate reported at 1-year. 80% of patients achieved greater than75% improvement, with 37% being completely dry. There were no serious adverse or unanticipated device related events. Detailed study results will be presented to interested parties by study investigators via an Axonics-hosted webinar to be announced in the coming weeks.

ShowHide Related Items >><<
AXNX Axonics
$39.12 /

-0.87 (-2.18%)

AXNX Axonics
$39.12 /

-0.87 (-2.18%)

04/21/20 Piper Sandler
Axonics price target lowered to $44 from $48 at Piper Sandler
04/14/20 Piper Sandler
Axonics next-gen INS not compatible with InterStim II leads, says Piper Sandler
04/08/20 Wells Fargo
Axonics price target lowered to $35 from $47 at Wells Fargo
03/05/20 Truist
Axonics price target raised to $48 from $38 at SunTrust
AXNX Axonics
$39.12 /

-0.87 (-2.18%)

  • 08
    May
  • 20
    Nov
AXNX Axonics
$39.12 /

-0.87 (-2.18%)

Earnings
Axonics reports preliminary Q2 revenue $15.2M, consensus $5.19M » 06:07
07/13/20
07/13
06:07
07/13/20
06:07
AXNX

Axonics

$39.35 /

-1.88 (-4.56%)

Sales to customers in the…

Sales to customers in the United States accounted for approximately 96% of total revenue. Raymond Cohen, CEO of Axonics, commented, "Axonics has stayed focused on supporting physicians and their patients during the COVID-19 pandemic, along with building finished goods inventory, signing agreements with national, regional and local hospital systems, and advancing regulatory filings with the FDA. In the second quarter, we continued to make meaningful progress on new customer acquisition, with over 45% of the top 1,000 centers in the United States now having implanted patients with the Axonics r-SNM System. While gross margins will be impacted by lower overhead absorption and other related factors, we are highly encouraged by the trajectory of new order flow in June. Given these factors, we are confident that Axonics is well positioned for growth in the second half of 2020, while recognizing that a sustained recovery in elective procedures is contingent on factors that are outside of our control." Cohen continued, "We continue to invest in innovation and enhancing the patient experience, having announced several recent FDA approvals that will accrue to SNM becoming the preferred therapy for overactive bladder and bowel dysfunction. The overwhelmingly positive feedback from clinicians and patients on their experience with our product in tandem with our commitment to increase patient awareness supports our conviction that the SNM market is poised for significant expansion in the years ahead."

ShowHide Related Items >><<
AXNX Axonics
$39.35 /

-1.88 (-4.56%)

AXNX Axonics
$39.35 /

-1.88 (-4.56%)

04/21/20 Piper Sandler
Axonics price target lowered to $44 from $48 at Piper Sandler
04/14/20 Piper Sandler
Axonics next-gen INS not compatible with InterStim II leads, says Piper Sandler
04/08/20 Wells Fargo
Axonics price target lowered to $35 from $47 at Wells Fargo
03/05/20 Truist
Axonics price target raised to $48 from $38 at SunTrust
AXNX Axonics
$39.35 /

-1.88 (-4.56%)

  • 08
    May
  • 20
    Nov
AXNX Axonics
$39.35 /

-1.88 (-4.56%)

Over a month ago
On The Fly
Fly Intel: After-Hours Movers » 18:55
07/01/20
07/01
18:55
07/01/20
18:55
VERO

Venus Concept

$3.21 /

-0.275 (-7.89%)

, FEIM

Frequency Electronics

$9.15 /

+ (+0.00%)

, NUS

Nu Skin

$38.48 /

+0.35 (+0.92%)

, FORM

FormFactor

$29.34 /

+0.01 (+0.03%)

, AXNX

Axonics

$36.38 /

+1.26 (+3.59%)

, LDOS

Leidos

$93.34 /

-0.39 (-0.42%)

, CULP

Culp, Inc.

$10.03 /

+1.375 (+15.89%)

, BLFS

BioLife Solutions

$16.09 /

-0.22 (-1.35%)

, PLYA

Playa Hotels & Resorts

$3.66 /

+0.03 (+0.83%)

, AKRO

Akero Therapeutics

$33.49 /

+8.64 (+34.77%)

, MCD

McDonald's

$184.50 /

+0.15 (+0.08%)

, FIZZ

National Beverage

$63.51 /

+2.34 (+3.83%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
VERO Venus Concept
$3.21 /

-0.275 (-7.89%)

PLYA Playa Hotels & Resorts
$3.66 /

+0.03 (+0.83%)

NUS Nu Skin
$38.48 /

+0.35 (+0.92%)

MCD McDonald's
$184.50 /

+0.15 (+0.08%)

LDOS Leidos
$93.34 /

-0.39 (-0.42%)

FORM FormFactor
$29.34 /

+0.01 (+0.03%)

FEIM Frequency Electronics
$9.15 /

+ (+0.00%)

CULP Culp, Inc.
$10.03 /

+1.375 (+15.89%)

BLFS BioLife Solutions
$16.09 /

-0.22 (-1.35%)

AXNX Axonics
$36.38 /

+1.26 (+3.59%)

AKRO Akero Therapeutics
$33.49 /

+8.64 (+34.77%)

VERO Venus Concept
$3.21 /

-0.275 (-7.89%)

03/31/20
Fly Intel: Top five analyst downgrades
03/31/20 Oppenheimer
Venus Concept downgraded to Perform at Oppenheimer as COVID-19 clouds outlook
03/31/20 Oppenheimer
Venus Concept downgraded to Perform from Outperform at Oppenheimer
01/09/20 Oppenheimer
Oppenheimer says has 'fundamentally positive' stance on Venus Concept
FEIM Frequency Electronics
$9.15 /

+ (+0.00%)

NUS Nu Skin
$38.48 /

+0.35 (+0.92%)

06/24/20 Citi
Nu Skin price target raised to $41 from $29 at Citi
05/07/20 Deutsche Bank
Nu Skin price target raised to $35 from $28 at Deutsche Bank
03/09/20 Deutsche Bank
Nu Skin downgraded to Hold from Buy at Deutsche Bank
02/13/20 DA Davidson
Nu Skin price target lowered to $35 from $42 at DA Davidson
FORM FormFactor
$29.34 /

+0.01 (+0.03%)

06/18/20 B. Riley FBR
FormFactor price target raised to $36 from $30 at B. Riley FBR
06/15/20 Stifel
FormFactor upgraded to Buy from Hold at Stifel
06/01/20 DA Davidson
FormFactor upgraded to Buy from Neutral at DA Davidson
06/01/20 DA Davidson
FormFactor upgraded to Buy from Neutral at DA Davidson
AXNX Axonics
$36.38 /

+1.26 (+3.59%)

04/21/20 Piper Sandler
Axonics price target lowered to $44 from $48 at Piper Sandler
04/14/20 Piper Sandler
Axonics next-gen INS not compatible with InterStim II leads, says Piper Sandler
04/08/20 Wells Fargo
Axonics price target lowered to $35 from $47 at Wells Fargo
03/05/20 Truist
Axonics price target raised to $48 from $38 at SunTrust
LDOS Leidos
$93.34 /

-0.39 (-0.42%)

06/11/20
Fly Intel: Top five analyst initiations
06/11/20 Baird
Baird starts Leidos at Outperform, sees growth poised to ramp next year
06/10/20 Baird
Leidos initiated with an Outperform at Baird
05/07/20
Fly Intel: Top five analyst initiations
CULP Culp, Inc.
$10.03 /

+1.375 (+15.89%)

05/28/20 Stifel
Culp upgraded to Buy from Hold at Stifel
02/19/20
Fly Intel: Top five analyst downgrades
02/19/20 Stifel
Culp, Inc. downgraded to Hold from Buy at Stifel
09/09/19 Raymond James
Culp, Inc. price target lowered to $18 from $22 at Raymond James
BLFS BioLife Solutions
$16.09 /

-0.22 (-1.35%)

05/15/20 Stephens
BioLife Solutions price target raised to $24 after 'strong' Q1 beat at Stephens
03/23/20 H.C. Wainwright
BioLife Solutions price target lowered to $17 from $26 at H.C. Wainwright
02/24/20 Lake Street
BioLife Solutions initiated with a Buy at Lake Street
02/19/20 Benchmark
BioLife Solutions initiated with a Buy at Benchmark
PLYA Playa Hotels & Resorts
$3.66 /

+0.03 (+0.83%)

04/29/20 Truist
Playa Hotels & Resorts downgraded to Hold from Buy at SunTrust
04/29/20 Truist
Playa Hotels & Resorts downgraded to Hold from Buy at SunTrust
04/07/20 Citi
Playa Hotels & Resorts downgraded to Sell from Neutral at Citi
04/03/20 Deutsche Bank
Playa Hotels & Resorts price target lowered to $7 from $11 at Deutsche Bank
AKRO Akero Therapeutics
$33.49 /

+8.64 (+34.77%)

07/01/20 JPMorgan
Akero Therapeutics price target raised to $41 from $28 at JPMorgan
07/01/20 Jefferies
Akero Therapeutics price target raised to $48 from $31 at Jefferies
07/01/20 Canaccord
Akero Therapeutics price target raised to $51 from $36 at Canaccord
07/01/20 H.C. Wainwright
Akero Therapeutics price target raised to $45 from $33 at H.C. Wainwright
MCD McDonald's
$184.50 /

+0.15 (+0.08%)

06/24/20 BMO Capital
McDonald's price target raised to $220 from $215 at BMO Capital
06/24/20 JPMorgan
McDonald's price target raised to $204 from $180 at JPMorgan
06/17/20 Morgan Stanley
McDonald's price target raised to $200 from $189 at Morgan Stanley
06/17/20 Truist
McDonald's price target raised to $208 from $195 at SunTrust
FIZZ National Beverage
$63.51 /

+2.34 (+3.83%)

05/18/20 Guggenheim
National Beverage price target raised to $38 from $34 at Guggenheim
11/18/19 Guggenheim
Coca-Cola's 'AHA' likely to take shelf space from LaCroix, says Guggenheim
11/11/19 Jefferies
National Beverage estimates and price target lowered at Jefferies
VERO Venus Concept
$3.21 /

-0.275 (-7.89%)

PLYA Playa Hotels & Resorts
$3.66 /

+0.03 (+0.83%)

NUS Nu Skin
$38.48 /

+0.35 (+0.92%)

MCD McDonald's
$184.50 /

+0.15 (+0.08%)

LDOS Leidos
$93.34 /

-0.39 (-0.42%)

FORM FormFactor
$29.34 /

+0.01 (+0.03%)

FIZZ National Beverage
$63.51 /

+2.34 (+3.83%)

CULP Culp, Inc.
$10.03 /

+1.375 (+15.89%)

BLFS BioLife Solutions
$16.09 /

-0.22 (-1.35%)

AXNX Axonics
$36.38 /

+1.26 (+3.59%)

AKRO Akero Therapeutics
$33.49 /

+8.64 (+34.77%)

  • 02
    Jul
  • 08
    May
  • 20
    Nov
MCD McDonald's
$184.50 /

+0.15 (+0.08%)

LDOS Leidos
$93.34 /

-0.39 (-0.42%)

PLYA Playa Hotels & Resorts
$3.66 /

+0.03 (+0.83%)

NUS Nu Skin
$38.48 /

+0.35 (+0.92%)

MCD McDonald's
$184.50 /

+0.15 (+0.08%)

LDOS Leidos
$93.34 /

-0.39 (-0.42%)

BLFS BioLife Solutions
$16.09 /

-0.22 (-1.35%)

AXNX Axonics
$36.38 /

+1.26 (+3.59%)

AKRO Akero Therapeutics
$33.49 /

+8.64 (+34.77%)

MCD McDonald's
$184.50 /

+0.15 (+0.08%)

FIZZ National Beverage
$63.51 /

+2.34 (+3.83%)

AKRO Akero Therapeutics
$33.49 /

+8.64 (+34.77%)

Hot Stocks
Axonics gets FDA approval for 3T full-body MRI scans » 16:01
07/01/20
07/01
16:01
07/01/20
16:01
AXNX

Axonics

$36.36 /

+1.24 (+3.53%)

Axonics Modulation…

Axonics Modulation Technologies announced that it has received FDA approval under a premarket approval supplement for 3T full-body magnetic resonance imaging conditional labeling for the Axonics r-SNM System. In September 2019, the FDA approved the Axonics r-SNM System with full-body conditional labeling for 1.5T MRI scanners. With this "incremental approval for 3T scans, the Axonics device continues to be the only SNM system available in the United States that is MRI compatible for both 1.5T and 3T full-body scans", the company states in its press release.

ShowHide Related Items >><<
AXNX Axonics
$36.36 /

+1.24 (+3.53%)

AXNX Axonics
$36.36 /

+1.24 (+3.53%)

04/21/20 Piper Sandler
Axonics price target lowered to $44 from $48 at Piper Sandler
04/14/20 Piper Sandler
Axonics next-gen INS not compatible with InterStim II leads, says Piper Sandler
04/08/20 Wells Fargo
Axonics price target lowered to $35 from $47 at Wells Fargo
03/05/20 Truist
Axonics price target raised to $48 from $38 at SunTrust
AXNX Axonics
$36.36 /

+1.24 (+3.53%)

  • 08
    May
  • 20
    Nov
AXNX Axonics
$36.36 /

+1.24 (+3.53%)

Hot Stocks
Axonics' wireless patient remote control approved by FDA » 06:03
06/03/20
06/03
06:03
06/03/20
06:03
AXNX

Axonics

$37.58 /

+0.69 (+1.87%)

Axonics announced FDA…

Axonics announced FDA approval of its new wireless patient Remote Control with SmartMRI technology for the Axonics r-SNM System under a premarket approval supplement. The new Remote Control simplifies the process by which patients can receive a full-body MRI. The new patient Remote Control with SmartMRI technology will be included in all new orders of the Axonics r-SNM System in the U.S. beginning this month. The Axonics r-SNM System is approved for 1.5T full-body MRI scans in the United States and both 1.5T and 3.0T full-body MRI scans in Canada and Europe.

ShowHide Related Items >><<
AXNX Axonics
$37.58 /

+0.69 (+1.87%)

AXNX Axonics
$37.58 /

+0.69 (+1.87%)

04/21/20 Piper Sandler
Axonics price target lowered to $44 from $48 at Piper Sandler
04/14/20 Piper Sandler
Axonics next-gen INS not compatible with InterStim II leads, says Piper Sandler
04/08/20 Wells Fargo
Axonics price target lowered to $35 from $47 at Wells Fargo
03/05/20 Truist
Axonics price target raised to $48 from $38 at SunTrust
AXNX Axonics
$37.58 /

+0.69 (+1.87%)

AXNX Axonics
$37.58 /

+0.69 (+1.87%)

Hot Stocks
Axonics announces publication of results from ARTISAN-SNM study » 06:05
05/19/20
05/19
06:05
05/19/20
06:05
AXNX

Axonics

$38.35 /

+2.56 (+7.15%)

Axonics Modulation…

Axonics Modulation Technologies announced the publication of the 1-year results from its ARTISAN-SNM study in the peer-reviewed journal Neurourology & Urodynamics. Axonics also plans to launch a multi-center registry study in the U.S to collect additional real-world clinical evidence on the performance, safety and patient experience with the Axonics r-SNM System across all approved indications to advance physician knowledge and patient access to rechargeable sacral neuromodulation therapy. Using a conservative "as treated" analysis method, the 1-year results found that 89% of all implanted patients with the Axonics r-SNM System had successful therapy outcomes, and 93% of treated patients were satisfied with their r-SNM therapy. Currently, 2-year follow-up visits in the ARTISAN study are ongoing.

ShowHide Related Items >><<
AXNX Axonics
$38.35 /

+2.56 (+7.15%)

AXNX Axonics
$38.35 /

+2.56 (+7.15%)

04/21/20 Piper Sandler
Axonics price target lowered to $44 from $48 at Piper Sandler
04/14/20 Piper Sandler
Axonics next-gen INS not compatible with InterStim II leads, says Piper Sandler
04/08/20 Wells Fargo
Axonics price target lowered to $35 from $47 at Wells Fargo
03/05/20 Truist
Axonics price target raised to $48 from $38 at SunTrust
AXNX Axonics
$38.35 /

+2.56 (+7.15%)

AXNX Axonics
$38.35 /

+2.56 (+7.15%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.